



**Figure S1. Caerulein-induced CP mouse model.** (A) Caerulein injection schedule. (B) Pancreas H&E and Picrosirius red staining of healthy c57bl/6j and caerulein-induced CP mice. Acinar cell atrophy (black arrows) and fibroblast/immune cell infiltrations (red arrows) are observed in CP mice. Brightfield 50x.



**Figure S2. Candidate clones grouping and fluorescent labeling.** (A) Candidate clones grouping based on sequence similarity by GibbsCluster Server 2.0. for group validation. (B) Table of fluorescent labeling of candidate phage clones. (C) Equations to calculate normalized percent injected dose (%ID) per tissue weight and VT680-to-VT750 ratio.



**B**


Group	# Dye per phage (CP; Healthy)	Phage injected (pfu) equil. to 1nmol dye (CP; Healthy)
1	182.44 ± 2925 191.36 ± 3708	3.08×10 <sup>11</sup> ± 4.17×10 <sup>10</sup> 2.93×10 <sup>11</sup> ± 5.44×10 <sup>10</sup>
2	233.43 ± 1923 215.99 ± 2035	4.32×10 <sup>11</sup> ± 1.42×10 <sup>11</sup> 4.82×10 <sup>11</sup> ± 1.24×10 <sup>11</sup>
3	234.32 ± 3121 212.04 ± 3568	3.14×10 <sup>11</sup> ± 7.68×10 <sup>10</sup> 4.02×10 <sup>11</sup> ± 5.10×10 <sup>10</sup>
4	240.93 ± 3701 203.53 ± 3550	3.36×10 <sup>11</sup> ± 8.78×10 <sup>10</sup> 4.35×10 <sup>11</sup> ± 6.76×10 <sup>10</sup>
WT	321.09 ± 4503 376.06 ± 2037	5.18×10 <sup>11</sup> ± 6.69×10 <sup>10</sup> 3.70×10 <sup>11</sup> ± 2.13×10 <sup>10</sup>

**C**

$$\begin{aligned}
 \%ID/g &= \frac{dye\ in\ panc}{phage\ injected \times dye/phage} \\
 &\times \frac{1}{mass\ panc} \times 100\%
 \end{aligned}$$


$$VT680\text{-to-}VT750\ ratio = \frac{\%ID/g\ VT680}{\%ID/g\ VT750}$$

**Figure S3. The size distribution of peptide modified liposomes detected by NanoSight.** (A) NP liposomes. (B) MDLSLKP liposomes. (C) MNSIAIP liposomes.



**Figure S4. Apigenin loading in peptide-modified liposomes.** (A) Chemical structure and (B) physicochemical properties of apigenin reported on PubChem. (C) A characteristic table shows the properties of apigenin-loaded liposomes. (D) The release profile of apigenin in PBS at 4C, pH7.4, from liposomes. N=3. (E) In vitro release study in 50% FBS at 37C. N =3.

**A**




**B**

Properties	Apigenin, C <sub>15</sub> H <sub>10</sub> O <sub>5</sub>
Molecular weight	270.24 g/mol
Water Solubility	0.183 g/mL
Charge (pH 7.4)	0
pKa	pKa <sub>1</sub> = 7.12; pKa <sub>2</sub> = 8.10
Log P	1.7


**C**

	No peptide liposomes	ECM liposomes
Size (nm)	93.1 ± 3.6	94.3 ± 1.4
Batch concentration (particle/mL)	1.09E+14	1.52E+14
Drug per liposome	33930	28501


**D**





**E**



**Figure S5. Targeted liposomal delivery of apigenin reduces hepatotoxicity.** (A) Chemistry test results generated from serum samples collected from vehicle, free drug-, Api-Naked Lip- and Api-ECM Lip-treated CP mice revealing a statically significant reduction of toxic effects of the apigenin-based treatment to the mice livers ( $p$ -value = 0.0196). No significant toxic effects induced to mice kidneys is observed in all treatments. Mean  $\pm$  SEM,  $N=3$ . (B) Representative H&E staining of livers. Scale bar: 100  $\mu$ m. (C) Western blot images and the quantification of liver lysates from treated CP mice probing for SOD1. Mean  $\pm$  SEM,  $N = 5$ ,  $*p$ -value = 0.0491.



**Figure S6. Fibronectin staining in tissues other than the pancreas.** (A) Images of liver, heart, and lung stained with fibronectin harvested from mice treated with vehicle, free Apigenin, Apigenin-encapsulated control liposomes, and Apigenin-encapsulated ECM liposomes. (B) Quantification of percent fibronectin-positive area in liver, heart, and lung. N = 4 images/group. ANOVA was used: p-value = 0.699 (liver), 0.777 (heart), and 0.074 (lung).



**Figure S7. Certificate of analysis of peptides synthesized by Tufts University. (A) MDLSLKPGGSK(FAM)C and (B) MNSIAIPGGSK(FAM)C.**

**A.**

**SynthAssist™**  
Peptide Synthesis

Report type: Sequence  
9/18/19 @ 3:17 PM  
File name: CP-RCM\_KELLY

Sequence editor: **MDLSLKP**  
Sequence: [H]-M-D-L-S-L-K-P-G-S-K-C-[NH2]  
Comments: CP-RCM  
K11+LYS 5/6-FAM  
Disulfide Bonds: 0  
Chemistry: Fmoc

Composition:  
Sequence: [H]-Met-Asp-Leu-Ser-Leu-Lys-Pro-Gly-Gly-Ser-Lys-Cys-[NH2]  
Composition: C48 H91 N15 O16 S2  
Weight: 1234.5060 + 554.4 = 1592.4  
C-Terminal: NH2  
N-Terminal: H  
# of Residues: 12  
AA List: AA Count  
Asp 1  
Cys 1  
Gly 2  
Leu 2  
Lys 2  
Met 1  
Pro 1  
Ser 2

Calculations:  
Sequence: [H]-Met-Asp(OtBu)-Leu-Ser(tBu)-Leu-Lys(Boc)-Pro-Gly-Gly-Ser(tBu)-Lys(Boc)-Cys(Trt)-[Amide Resin]  
Chemistry: Fmoc  
Resin Type: Amide Resin  
Resin Subst.: 0.612 mmol/g  
Resin moles: 0.100 mmol  
Resin Weight: 0.163 grams  
Blank Abs.: 0.000  
Sample Volume: 5.0 mL

Cy	Amino Acid	Resin Eq. Wt.	Subst. mmol/g	R.S. mg	mmol	Weight grams	A570	Amine umol	Percent Coupling
1	Cys(Trt)	1979.45	0.505	0.000	0.100	0.198			

SynthAssist™ Software V1.0.0 Applied Biosystems, Inc © 1991 All Page 1 of 2

**SynthAssist™**  
Peptide Synthesis

Report type: Sequence  
9/18/19 @ 3:17 PM  
File name: CP-RCM\_KELLY

2	Lys(Boc)	2207.74	0.453	0.000	0.100	0.221			
3	Ser(tBu)	2350.93	0.425	0.000	0.100	0.235			
4	Gly	2407.98	0.415	0.000	0.100	0.241			
5	Gly	2465.04	0.406	0.000	0.100	0.247			
6	Pro	2562.15	0.390	0.000	0.100	0.256			
7	Lys(Boc)	2790.45	0.388	0.000	0.100	0.279			
8	Leu	2903.61	0.344	0.000	0.100	0.290			
9	Ser(tBu)	3046.79	0.328	0.000	0.100	0.305			
10	Leu	3159.95	0.316	0.000	0.100	0.316			
11	Asp(OtBu)	3331.15	0.300	0.000	0.100	0.333			
12	Met	3462.35	0.289	0.000	0.100	0.346			
>	H	3241.11	0.309	0.000	0.100	0.324			

Total: 00.00

SynthAssist™ Software V1.0.0 Applied Biosystems, Inc © 1991 All Page 2 of 2

**B.**

**SynthAssist™**  
Peptide Synthesis

Report type: Sequence  
9/18/19 @ 3:15 PM  
File name: CP-ACT\_KELLY

Sequence editor: **MNSIAIP**  
Sequence: [H]-M-N-S-I-A-I-P-G-S-K-C-[NH2]  
Comments: CP-ACT  
K11+LYS 5/6-FAM  
Disulfide Bonds: 0  
Chemistry: Fmoc

Composition:  
Sequence: [H]-Met-Ans(Trt)-Ser(tBu)-Ile-Ala-Ile-Pro-Gly-Gly-Ser-Lys-Cys-[NH2]  
Composition: C48 H85 N15 O15 S2  
Weight: 1176.4256 + 354.4 = 1534.4  
C-Terminal: NH2  
N-Terminal: H  
# of Residues: 12  
AA List: AA Count  
Ala 1  
Ans 1  
Cys 1  
Gly 2  
Ile 2  
Lys 1  
Met 1  
Pro 1  
Ser 2

Calculations:  
Sequence: [H]-Met-Ans(Trt)-Ser(tBu)-Ile-Ala-Ile-Pro-Gly-Gly-Ser(tBu)-Lys(Boc)-Cys(Trt)-[Amide Resin]  
Chemistry: Fmoc  
Resin Type: Amide Resin  
Resin Subst.: 0.612 mmol/g  
Resin moles: 0.100 mmol  
Resin Weight: 0.163 grams  
Blank Abs.: 0.000  
Sample Volume: 5.0 mL

Cy	Amino Acid	Resin Eq. Wt.	Subst. mmol/g	R.S. mg	mmol	Weight grams	A570	Amine umol	Percent Coupling
1	Cys(Trt)	1979.45	0.505	0.000	0.100	0.198			

SynthAssist™ Software V1.0.0 Applied Biosystems, Inc © 1991 All Page 1 of 2

**SynthAssist™**  
Peptide Synthesis

Report type: Sequence  
9/18/19 @ 3:15 PM  
File name: CP-ACT\_KELLY

1	Cys(Trt)	1979.45	0.505	0.000	0.100	0.198			
2	Lys(Boc)	2207.74	0.453	0.000	0.100	0.221			
3	Ser(tBu)	2350.93	0.425	0.000	0.100	0.235			
4	Gly	2407.98	0.415	0.000	0.100	0.241			
5	Gly	2465.04	0.406	0.000	0.100	0.247			
6	Pro	2562.15	0.390	0.000	0.100	0.256			
7	Ile	2675.31	0.374	0.000	0.100	0.268			
8	Ala	2746.39	0.364	0.000	0.100	0.275			
9	Ile	2859.55	0.350	0.000	0.100	0.286			
10	Ser(tBu)	3003.74	0.333	0.000	0.100	0.300			
11	Ans(Trt)	3359.17	0.298	0.000	0.100	0.326			
12	Met	3490.36	0.287	0.000	0.100	0.349			
>	H	3269.13	0.306	0.000	0.100	0.327			

Total: 00.00

SynthAssist™ Software V1.0.0 Applied Biosystems, Inc © 1991 All Page 2 of 2

**Table S1. Phage clone individual validation raw data and calculation.**

Phage	Mouse model	Organ		Targeting Phage-VT680				M13Ke Phage-VT750				Radiant efficiency Targeting:M13Ke
		Organ	weight (mg)	# of phage injected	# dye/phage	IVIS readouts: total radiant efficiency	Normalized radiant efficiency*	# of phage injected	# dye/phage	IVIS readouts: total radiant efficiency	Normalized radiant efficiency*	
HPYSPLR	CP	Liver	898.12	4.0E+11	144.97	8.81E+09	1.69E-04	4.0E+11	372.35	3.82E+10	2.86E-04	0.59
		Pancreas	391.21	4.0E+11	144.97	7.09E+09	3.13E-04	4.0E+11	372.35	2.84E+09	4.87E-05	6.42
		Spleen	67.22	4.0E+11	144.97	3.75E+09	9.61E-04	4.0E+11	372.35	3.10E+09	3.10E-04	3.10
	Healthy	Liver	394.32	4.0E+11	140.20	1.48E+10	6.71E-04	4.0E+11	406.94	5.42E+10	8.44E-04	0.80
		Pancreas	52.36	4.0E+11	140.20	2.77E+09	9.44E-04	4.0E+11	406.94	1.94E+09	2.27E-04	4.16
		Spleen	103.91	4.0E+11	140.20	3.92E+09	6.73E-04	4.0E+11	406.94	4.18E+09	2.47E-04	2.73
KTYVPTT	CP	Liver	854.8	4.0E+11	167.47	1.11E+10	1.93E-04	4.0E+11	372.35	4.02E+10	3.16E-04	0.61
		Pancreas	218.97	4.0E+11	167.47	8.11E+09	5.53E-04	4.0E+11	372.35	1.51E+09	4.64E-05	11.90
		Spleen	85.2	4.0E+11	167.47	3.58E+09	6.28E-04	4.0E+11	372.35	2.61E+09	2.06E-04	3.05
	Healthy	Liver	1067.16	4.0E+11	167.47	1.18E+10	1.65E-04	4.0E+11	381.14	5.10E+10	3.13E-04	0.53
		Pancreas	410.1	4.0E+11	167.47	3.65E+09	1.33E-04	4.0E+11	381.14	9.51E+08	1.52E-05	8.74
		Spleen	98.27	4.0E+11	167.47	7.17E+09	1.09E-03	4.0E+11	381.14	4.76E+09	3.18E-04	3.43
MDLSLKP	CP	Liver	780.82	4.0E+11	146.93	8.22E+09	1.79E-04	4.0E+11	372.35	2.91E+10	2.50E-04	0.72
		Pancreas	243.54	4.0E+11	146.93	5.85E+09	4.09E-04	4.0E+11	372.35	1.37E+09	3.77E-05	10.85
		Spleen	80.31	4.0E+11	146.93	5.25E+09	1.11E-03	4.0E+11	372.35	4.92E+09	4.11E-04	2.70
	Healthy	Liver	1012.42	4.0E+11	146.93	8.59E+09	1.44E-04	4.0E+11	372.35	4.16E+10	2.76E-04	0.52
		Pancreas	264.06	4.0E+11	146.93	4.36E+09	2.81E-04	4.0E+11	372.35	1.91E+09	4.85E-05	5.79
		Spleen	91.74	4.0E+11	146.93	3.35E+09	6.22E-04	4.0E+11	372.35	3.64E+09	2.66E-04	2.34
SLPLGPM	CP	Liver	1006.12	4.0E+11	257.35	1.81E+10	1.75E-04	4.0E+11	372.35	4.12E+10	2.75E-04	0.64
		Pancreas	322.24	4.0E+11	257.35	7.93E+09	2.39E-04	4.0E+11	372.35	1.79E+09	3.72E-05	6.42
		Spleen	90.42	4.0E+11	257.35	9.12E+09	9.79E-04	4.0E+11	372.35	3.78E+09	2.81E-04	3.49
	Healthy	Liver	980.82	4.0E+11	257.35	2.24E+10	2.21E-04	4.0E+11	381.14	4.79E+10	3.20E-04	0.69
		Pancreas	343.27	4.0E+11	257.35	3.83E+09	1.08E-04	4.0E+11	381.14	1.13E+09	2.17E-05	5.00
		Spleen	95.61	4.0E+11	257.35	7.60E+09	7.72E-04	4.0E+11	381.14	3.92E+09	2.69E-04	2.87
HSGLNKQ	CP	Liver	240.02	4.0E+11	141.41	8.85E+09	6.51E-04	4.0E+11	372.81	3.70E+10	1.03E-03	0.63
		Pancreas	40.94	4.0E+11	141.41	4.99E+09	2.15E-03	4.0E+11	372.81	2.17E+09	3.55E-04	6.07
		Spleen	802.42	4.0E+11	141.41	4.69E+09	1.03E-04	4.0E+11	372.81	3.62E+09	3.02E-05	3.42
	Healthy	Liver	842.48	4.0E+11	106.78	6.03E+09	1.68E-04	4.0E+11	372.35	4.18E+10	3.33E-04	0.50
		Pancreas	239.5	4.0E+11	106.78	4.25E+09	4.16E-04	4.0E+11	372.35	1.49E+09	4.19E-05	9.93
		Spleen	90.63	4.0E+11	106.78	3.45E+09	8.92E-04	4.0E+11	372.35	4.07E+09	3.01E-04	2.96
MNSIAIP	CP	Liver	257.09	4.0E+11	115.32	9.36E+09	7.89E-04	4.0E+11	372.81	4.96E+10	1.29E-03	0.61
		Pancreas	45.9	4.0E+11	115.32	6.63E+09	3.13E-03	4.0E+11	372.81	2.19E+09	3.19E-04	9.81
		Spleen	887.72	4.0E+11	115.32	2.27E+09	5.54E-05	4.0E+11	372.81	2.03E+09	1.53E-05	3.61
	Healthy	Liver	758.75	4.0E+11	151.45	8.22E+09	1.79E-04	4.0E+11	372.35	3.79E+10	3.35E-04	0.53
		Pancreas	309.56	4.0E+11	151.45	3.98E+09	2.12E-04	4.0E+11	372.35	1.94E+09	4.20E-05	5.04
		Spleen	77.89	4.0E+11	151.45	3.93E+09	8.34E-04	4.0E+11	372.35	2.22E+09	1.91E-04	4.36
SANITNL	CP	Liver	377.24	4.0E+11	136.80	1.31E+10	6.35E-04	4.0E+11	372.81	4.82E+10	8.57E-04	0.74
		Pancreas	35.65	4.0E+11	136.80	3.74E+09	1.92E-03	4.0E+11	372.81	2.54E+09	4.77E-04	4.02
		Spleen	867.87	4.0E+11	136.80	5.11E+09	1.08E-04	4.0E+11	372.81	3.03E+09	2.34E-05	4.60
	Healthy	Liver	829.3	4.0E+11	87.24	6.56E+09	2.27E-04	4.0E+11	372.35	4.86E+10	3.93E-04	0.58
		Pancreas	375.21	4.0E+11	87.24	3.27E+09	2.50E-04	4.0E+11	372.35	3.27E+09	5.85E-05	4.27
		Spleen	87.12	4.0E+11	87.24	2.61E+09	8.59E-04	4.0E+11	372.35	3.68E+09	2.83E-04	3.03
SLTNSSF	CP	Liver	961.08	2.5E+11	182.53	1.82E+10	4.43E-04	2.5E+11	381.14	3.01E+10	3.34E-04	1.33
		Pancreas	217.65	2.5E+11	182.53	1.35E+09	1.45E-04	2.5E+11	381.14	3.33E+08	1.63E-05	8.86
		Spleen	93.18	2.5E+11	182.53	1.11E+09	2.78E-04	2.5E+11	381.14	9.19E+08	1.05E-04	2.65
	Healthy	Liver	810.23	4.0E+11	447.23	9.27E+09	6.39E-05	4.0E+11	372.35	7.25E+09	6.01E-05	1.06
		Pancreas	314.3	4.0E+11	447.23	7.86E+09	1.40E-04	4.0E+11	372.35	4.04E+09	8.63E-05	1.62
		Spleen	108.22	4.0E+11	447.23	7.59E+09	3.92E-04	4.0E+11	372.35	2.35E+09	1.46E-04	2.69
SNSQDLH	CP	Liver	302.49	4.0E+11	167.62	1.31E+10	6.45E-04	4.0E+11	372.81	3.98E+10	8.82E-04	0.73
		Pancreas	28.81	4.0E+11	167.62	4.05E+09	2.10E-03	4.0E+11	372.81	1.45E+09	3.37E-04	6.22
		Spleen	962.65	4.0E+11	167.62	7.33E+09	1.13E-04	4.0E+11	372.81	4.98E+09	3.47E-05	3.27
	Healthy	Liver	820.63	4.0E+11	142.64	8.55E+09	1.82E-04	4.0E+11	372.35	4.35E+10	3.56E-04	0.51
		Pancreas	336.62	4.0E+11	142.64	1.43E+09	7.43E-05	4.0E+11	372.35	1.80E+09	3.59E-05	2.07
		Spleen	70.03	4.0E+11	142.64	2.80E+09	7.00E-04	4.0E+11	372.35	2.35E+09	2.25E-04	3.11

\*Normalized radiant efficiency = total radiant efficiency/(# of phage injected × # of dye/phage × tissue weight in gram)



**Table S1. Phage clone individual validation raw data and calculation (continued).**

**CP-to-healthy ratio = normalized radiant efficiency of CP / normalized radiant efficiency of healthy tissue**

Phage	CP-to-healthy Ratio		
	Liver	Pancreas	Spleen
HPYSPLR	0.744	1.544	1.138
KTYVPTT	1.161	1.362	0.890
MDLSLKP	1.370	1.875	1.156
SLPLGPM	0.921	1.286	1.215
HSGLNKQ	1.254	0.611	1.157
MNSIAIP	1.144	1.945	0.829
SANITNL	1.287	0.943	1.518
SLTNSSF	1.248	5.469	0.985
SNSQDLH	1.428	3.009	0.165

**Table S2. P-values of statistical tests performed on Manders' correlation coefficients of phage clones overlapping with cell markers.** One-way ANOVA and Tukey-Kramer method were used for all tests. The result was considered significant if the p-value  $\leq 0.05$ . ns: not statistically significant.

Figure	Phage clone	MCC Comparison	Adjusted P-value	Summary
Figure 3B	MDLSLKP	Col IIIa vs $\alpha$ SMA	<0.0001	****
Figure 3B		Col IIIa vs CD31	<0.0001	****
Figure 3B		Col IIIa vs CK7	<0.0001	****
Figure 3B		Col IIIa vs CPA-1	<0.0001	****
Figure 3B		Col IIIa vs F4/80	<0.0001	****
Figure 3B	SLPLGPM	F4/80 vs $\alpha$ SMA	0.0023	**
Figure 3B		F4/80 vs CD31	0.0448	*
Figure 3B		F4/80 vs CK7	<0.0001	****
Figure 3B		F4/80 vs Col IIIa	0.0284	*
Figure 3B		F4/80 vs CPA-1	0.4832	ns
Figure 3B	HPYSPLR	F4/80 vs $\alpha$ SMA	<0.0001	****
Figure 3B		F4/80 vs CD31	0.8189	ns
Figure 3B		F4/80 vs CK7	<0.0001	****
Figure 3B		F4/80 vs Col IIIa	0.082	ns
Figure 3B		F4/80 vs CPA-1	0.0342	*
Figure 3B	KTYVPTT	$\alpha$ SMA vs CD31	<0.0001	****
Figure 3B		$\alpha$ SMA vs CK7	<0.0001	****
Figure 3B		$\alpha$ SMA vs Col IIIa	0.0003	***
Figure 3B		$\alpha$ SMA vs CPA-1	0.0006	***
Figure 3B		$\alpha$ SMA vs F4/80	0.0095	**
Figure 3B	SLTNSSF	F4/80 vs $\alpha$ SMA	<0.0001	****
Figure 3B		F4/80 vs CD31	<0.0001	****
Figure 3B		F4/80 vs CK7	<0.0001	****
Figure 3B		F4/80 vs Col IIIa	<0.0001	****
Figure 3B		F4/80 vs CPA-1	<0.0001	****
Figure 3B	MNSIAIP	CPA-1 vs $\alpha$ SMA	<0.0001	****
Figure 3B		CPA-1 vs CD31	<0.0001	****
Figure 3B		CPA-1 vs CK7	<0.0001	****
Figure 3B		CPA-1 vs Col IIIa	<0.0001	****
Figure 3B		CPA-1 vs F4/80	0.0002	***
Figure 3B	SNSQDLH	F4/80 vs $\alpha$ SMA	<0.0001	****
Figure 3B		F4/80 vs CD31	<0.0001	****
Figure 3B		F4/80 vs CK7	<0.0001	****
Figure 3B		F4/80 vs Col IIIa	<0.0001	****
Figure 3B		F4/80 vs CPA-1	<0.0001	****

**Table S3. P-values of statistical tests performed on Manders' correlation coefficients of liposomes overlapping with cell markers.** One-way ANOVA and Tukey-Kramer method were used for all tests. The result was considered significant if the p-value  $\leq 0.05$ . ns: not statistically significant.

Figure	Liposome	MCC Comparison	Adjusted P-value	Summary
Figure 5B	MDLSLKP	Col IIIa vs $\alpha$ SMA	<0.0001	****
Figure 5B		Col IIIa vs CD31	<0.0001	****
Figure 5B		Col IIIa vs CK7	<0.0001	****
Figure 5B		Col IIIa vs CPA-1	<0.0001	****
Figure 5B		Col IIIa vs F4/80	0.0012	**
Figure 5B	MNSIAIP	CPA-1 vs $\alpha$ SMA	0.0005	***
Figure 5B		CPA-1 vs CD31	0.3179	ns
Figure 5B		CPA-1 vs CK7	0.0013	**
Figure 5B		CPA-1 vs Col IIIa	0.9882	ns
Figure 5B		CPA-1 vs F4/80	0.9746	ns
Figure 5B	NC Liposome	F4/80 vs $\alpha$ SMA	<0.0001	****
Figure 5B		F4/80 vs CD31	<0.0001	****
Figure 5B		F4/80 vs CK7	<0.0001	****
Figure 5B		F4/80 vs Col IIIa	<0.0001	****
Figure 5B		F4/80 vs CPA-1	<0.0001	****